Back to Newsroom

Debiopharm Group and Nobelex Biotech Start Two Collaborations on Development of New Antibiotics Against N. Gonorrhoeae and Enteric Species

Lausanne, Switzerland and Toronto, Canada – June 26, 2014 – Debiopharm Group™ (Debiopharm), a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, and Nobelex Biotech Inc. (Nobelex), a Canadian company focusing on the discovery and early development of novel antimicrobial drugs, today announced their collaboration for two discovery programs to develop antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action.

Click here to read more